MRP与肺癌分化程度、临床分期、淋巴结转移关系的Meta分析

目的从循证医学角度综合分析MRP（多药耐药相关蛋白）与肺癌分化程度、临床分期、淋巴结转移的相关性,预测肺癌化疗的预后。方法采用Meta分析对有关MRP与人肺癌分化程度、TNM分期、淋巴结转移的文献进行综合分析。结果共纳入16个研究,MRP在低分化肺癌组织中的阳性表达率是高分化组织的1.62倍OR=1.62,95%CI（1.29,2.04）];在Ⅲ-Ⅳ期肺癌组织中的阳性表达率是Ⅰ-Ⅱ期的1.54倍OR=1.54,95%CI（1.23,1.93）];而与有无淋巴结转移无相关性OR=0.84,95%CI（0.55,1.27）]。结论 MRP的表达与肺癌组织的分化程度及临床分期存在一定的相关性,而与有无淋巴结转移无关,提示MRP可能成为一项判断肺癌预后的指标。

A Meta-analysis on the Relationship between MRP and Differentiation Level,TNM stages and Lymph Node Metastasis of Lung Cancer

【Objective】 To understand the relationship between multidrug-resistance protein（MRP） and differentiation level,TNM stages and lymph node metastasis of lung cancer based on evidence-based medicine and predict the prognosis of chemotherapy.【Methods】 Comprehensively analyzed the literatures about differentiation level,TNM stages and lymph node metastasis of lung cancer.【Results】 16 studies were included.Expression level of MRP in poorly differentiated cancer tissue is 1.62 times than that in well-differentiated tissue,in Ⅲ-Ⅳstage cancer tissue is 1.54 times than that in Ⅲ-Ⅳstage tissue,while there was no relevance between MRP and lymph node metastasis.【Conclusion】 The expression of MRP has relationship with differentiation level and TNM stages,no relationship with lymph node metastasis,which indicate that MRP may determine the prognosis of lung cancer.